Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...

Pfizer eventually increased its offer. The company is now set to acquire Metsera in a deal worth up to $10 billion, including ...

Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Oliver Barnes Pfizer and Novo Nordisk duked it out for who will own Metsera — a coveted biotech that’s developing ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...